Document:

Exhibit
10.09

 

LICENSE,
FUNDING AND OPERATIONAL AGREEMENT

 

This
License Agreement (this “Agreement”) is made and is effective this 1st day of October 2021, (the “Effective
Date”) between Mid-Atlantic BioTherapeutics, Inc (hereinafter MABT), a Delaware corporation (“Licensor”)
and Curative Biotechnology, Inc. (hereinafter CUBT), a Delaware corporation (“Licensee”), and David Horn, LLC as Licensor
to MABT, and their respective legitimate successors and/or assigns. Licensors and Licensee are each referred to as a “Party”
and collectively referred to as the “Parties.”

 

WHEREAS,
Licensor owns the Licensed Patent Rights and Licensed Know-How, as defined herein;

 

WHEREAS,
Licensee desires to obtain a license to develop Licensed Products in the Field of Use on the terms and conditions set forth in this Agreement;
and

 

WHEREAS,
Licensor is willing to grant Licensee such license on the terms and conditions set forth in this Agreement; and

 

WHEREAS,
Licensee has agreed to use its best efforts to raise the funding needed to accomplish the goals set forth herein;

 

NOW
THEREFORE, in consideration of the premises and the mutual covenants set forth herein, the receipt and sufficiency of which are hereby
acknowledged, Licensor and Licensee agree as follows:

 

1.
Definitions.

 

1.1
“Affiliate” means, with respect to a Party, any Person that controls, is controlled by, or is under common control
with such Party. For purposes of this Section 1.1, “control” shall refer to (a) in the case of a Person that is a corporate
entity, direct or indirect ownership of fifty percent (50%) or more of the stock or shares having the right to vote for the election
of directors of such Person and (b) in the case of a Person that is not a corporate entity, the possession, directly or indirectly, of
the power to direct, or cause the direction of, the management or policies of such Person, whether through the ownership of voting securities,
by contract or otherwise.

 

1.2
“Competitive Infringement” shall have the meaning set forth in Section 5.2(a).

 

1.3
“Confidential Information” means any confidential or proprietary information furnished by one Party to the other Party
in connection with this Agreement, provided that such information is specifically designated as “confidential”, “proprietary”
or the like. Confidential Information includes, without limitation:

 

(a)
non-public information disclosed by either Party in reports submitted by Licensee or Licensor pursuant to Section 3.4(a) and through
audits conducted by either Party pursuant to Section 3.4(b); and the Licensed Know-How.

 

1.4
“Cover,” “Covering” or “Covered” means, with respect to a product, that, in
the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such
product would infringe such Valid Claim (or, with respect to a patent application, would infringe such Valid Claim if the patent application
were to issue as a patent).

 

    	-1-

    	 

    

 

1.5
“Field of Use” means the rights for the development and commercialization of MABT’s COVID-19 vaccine composed
of recombinant S1 and S2 proteins from SARS-CoV-2 plus IMT504 adjuvant.

 

1.6
“IMT504” means (i) the pharmaceutical compound known as IMT504 described in the Licensed Patent Rights and (ii) any
compounds other than IMT504 that are Covered by the Licensed Patent Rights.

 

1.7
“IND” means an investigational new drug application in the United States, including any successor application thereof,
and any comparable application in any country or regulatory jurisdiction outside the United States.

 

1.8
“License” means the license granted to Licensee in Section 2.1.

 

1.9
“Licensed Know-How” means the documented information, techniques, technology, practices, trade secrets, inventions,
data, results and records in Licensor’s possession and control as of the Effective Date or at any time during the Term relating
to the inventions claimed or described in the Licensed Patent Rights.

 

1.10
“Licensed Patent Rights” means the patent rights set forth on Exhibit A as intended for the Field of Use, and
any other patents subsequently filed by Licensor which apply to the Field of Use and are required to develop Licensed Product.

 

1.11
“Licensed Product” means MABT’s COVID-19 vaccine composed of recombinant S1 and S2 proteins from SARS-CoV-2
plus IMT504 adjuvant.

 

1.12
“Licensee Improvement” means any and all developments, derivatives, enhancements, modifications, inventions patents
and patent rights or discoveries relating to Licensed Product and developed, or created by or on behalf of Licensee, or any of its subsidiaries
or its sublicensees at any time during the Term, whether patentable or not, including developments, inventions and discoveries intended
to enhance the safety, efficacy, delivery and bioavailability of Licensed Product.

 

1.13
“Licensee Improvement Know-How” means the documented information, techniques, technology, practices, trade secrets,
inventions, data, results and records in Licensee’s possession and control at any time during the Term relating to a Licensee.

 

1.14
“Net Profits, with respect to a Licensed Product, shall be determined from the books and records of Licensee, Licensor and
their Affiliates and Sublicensees and all interpretations and calculations hereunder shall be computed according to Generally Accepted
Accounting Principles, consistently applied.

 

    	-2-

    	 

    

 

In
the event the Licensed Product is sold as part of a Combination Product, such “Combination Product” means a combination of
a Licensed Product with another product (including in the case of a drug, another active ingredient) which is not a Licensed Product,
the Net Profits from the Combination Product, for the purposes of determining royalty payments, shall be determined by multiplying the
Net Profits (as determined above) of the Combination Product, during the applicable royalty reporting period, by the fraction, A/A+B,
where A is the average sale price of the Licensed Product when sold separately in finished form and B is the average sale price of the
other product included in the Combination Product when sold separately in finished form, in each case during the applicable royalty reporting
period or, if sales of both the Licensed Product and the other product did not occur in such period, then in the most recent royalty
reporting period in which sales of both occurred. In the event that such average sale price cannot be determined for both the Licensed
Product and all other products included in such Combination Product, Net Profits for the purposes of determining royalty payments shall
be calculated by multiplying the Net Profits of the Combination Product by the fraction of C/C+D where C is the fair market value of
the Licensed Product and D is the fair market value of all other products included in the Combination Product. In such event, Licensee
shall in good faith make a determination of the respective fair market values of the Licensed Product and all other products included
in the Combination Product and shall notify Licensor of such determination and provide Licensor with data to support such determination.
Licensor shall have the right to review such determination of fair market values and, if Licensor disagrees with such determination,
to notify Licensee of such disagreement within sixty (60) days after Licensee notifies Licensor of such determination. If Licensor notifies
Licensee that Licensor disagrees with such determination within such sixty (60) day period and if thereafter the Parties are unable to
agree in good faith as to such respective fair market values, then such matter shall be resolved as provided in Section 10.10. If Licensor
does not notify Licensee that Licensor disagrees with such determination within such sixty (60) day period, such determination shall
be conclusive and binding on the Parties.

 

1.15
“Person” means any natural person or any corporation, company, partnership, joint venture, firm or other entity, including
without limitation a Party.

 

1.16
“Regulatory Approval” means the approvals (including any applicable governmental price and reimbursement approvals),
licenses, registrations or authorizations of Regulatory Authorities necessary for the development, manufacture, use, offer for sale,
sale or importation of a product in a country or territory.

 

1.17
“Regulatory Authority” means a federal, national, multinational, state, provincial or local regulatory agency, department,
bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing or sale
of a product in a Territory.

 

1.18
“Term” shall have the meaning set forth in Section 12.1.

 

1.19
“Territory” means the entire world.

 

1.20
“Third Party” means any Person other than a Party or any of its Affiliates.

 

    	-3-

    	 

    

 

1.21
“Valid Claim” means (a) a claim of an issued patent in the U.S. or in a jurisdiction outside the U.S., as applicable,
that has not expired, lapsed, been cancelled or abandoned, or been dedicated to the public, disclaimed, or held unenforceable, invalid,
revoked or cancelled by a court or administrative agency of competent jurisdiction in an order or decision from which no appeal has been
or can be taken, including through opposition, reexamination, reissue or disclaimer; or (b) a claim of a pending patent application that
has not been finally abandoned or finally rejected or expired and which has been pending for no more than seven (7) years from the date
of filing of the earliest priority patent application to which such pending patent application is entitled to claim benefit.

 

2.
Grant of License; Diligence.

 

2.1
License. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive, non-transferable
(except as set forth in Section 13.3), right and license, under the Licensed Patent Rights and Licensed Know-How, to make, have made,
use, offer for sale, sell and import in the Territory, Licensed Products solely in the Field of Use.

 

In
the event that Licensor, MABT, defaults on provisions of the License Agreement between David Horn, LLC and MABT, such default shall not
impair the rights and obligations of the Parties to this Agreement, and David Horn, LLC, shall fulfill the obligations under this Agreement
to Licensee. David Horn, LLC, in such event, shall assume the rights of Licensor under this Agreement.

 

2.2
Sublicensing. Licensee shall have the right to grant sublicenses under the License with the prior written approval of Licensor,
which shall not be unreasonably withheld, conditioned or delayed.

 

2.3
Diligence. Licensee shall use commercially reasonable efforts to develop and commercialize Licensed Products in the Field of Use,

 

2.4
No Additional Rights. Nothing in this Agreement shall be construed to confer any rights upon Licensee by implication, estoppel
or otherwise as to any technology or Patent Rights of Licensor or any other entity other than the Licensed Patent Rights, regardless
of whether such technology or Patent Rights shall be dominant or subordinate to any Licensed Patent Rights.

 

2.5
Grant to Licensor of License to Licensee Improvements. Licensee hereby grants to Licensor an unrestricted, fully paid-up, non-royalty-bearing,
perpetual, exclusive, worldwide right and license, under the Licensee Improvement and Licensee Improvement Know-How, for any and all
patents ultimately required to develop Licensed Product in the Field of Use, whether currently included in Exhibit A or not; with the
right to grant sublicenses, to practice Licensee Improvements and to make, have made, use, offer for sale, sell and import in the Territory
and to otherwise exploit Licensee Improvements.

 

3.
Payments.

 

3.1
Equity Payments. As partial consideration for the License and other acts of Licensor required hereunder, Licensee shall issue
to Licensor Milestone Payments through the issue of its unregistered securities as set forth below in Section 3.2.

 

    	-4-

    	 

    

 

3.2
Milestone Payments. Licensee shall pay to Licensor, within ten (10) days after achievement of the corresponding milestone, each
of the following one-time, non-refundable milestone equity payments by the issuance of the following amount of Licensee’s securities:

 

	Milestone
    Event 	 	Milestone
    Payment
	 	 	 
	1.
    Execution of this agreement	 	12.5
    million shares of Licensees common stock
	 	 	 
	2.
    Successful Investigational New Drug Application (“IND”) to FDA; “Successful” means FDA acceptance for the
    Parties to proceed to human testing	 	17.5
    million shares of Licensees common stock

 

3.3
Profit Sharing from Sale of Licensed Products. On a Licensed Product-by-Licensed Product and country-by-country basis, all Net
Profits from the sale of any Licensed Product shall be payable 50% to Licensor and 50% to Licensee, with only one exception. In the event
that the agreed upon budget is funded in full by CUBT and more funding is required, and CUBT or MABT provides that funding, CUBT or MABT
shall be entitled to a distribution of Net Profits equal to a simple interest annual return of 5% on that excess funding, in addition
to the return of the amount of the excess funding, prior to the 50/50 distribution anticipated by this provision.

 

3.4
Reports and Accounting.

 

(a)
Reports and Payments. Licensee and Licensor shall provide to the other Party, within thirty (30) days after the end of each calendar
quarter, reasonably detailed written accountings of Net Profit of the Licensed Products for such calendar quarter. Such quarterly reports
shall indicate (i) gross sales and Net Profit on a Licensed Product-by-Licensed Product and country-by-country basis, and (ii) the calculation
of Net Profit. When either Party delivers such accounting to the other Party such report, the reporting Party shall also deliver all
amounts due under Section 3.3 to the other Party for the calendar quarter.

 

(b)
Audits by the Parties. Each Party shall keep, and shall require its Affiliates and Sublicensees to keep, records of the latest
three (3) years relating to gross sales, Net Profit, and all information relevant under Section 3.3. For the sole purpose of verifying
amounts payable to the other Party, each Party shall have the right no more than once each calendar year, at the reviewing Party’s
expense, to review, together with its accountants, such records in the location(s) where such records are maintained by the other Party
and its Affiliates and Sublicensees upon reasonable notice and during regular business hours. Results of such review shall be made available
to the reviewed Party. If the review reflects an underpayment to the other Party, such underpayment shall be promptly remitted to other
Party together with 5% interest.

 

3.5
Taxes.

 

(a)
Any amounts to be paid hereunder are stated before value added tax, goods and services tax, sales, export or import duties or any similar
tax or duties, which will be paid by Licensee at the rate and in the manner from time to time prescribed by applicable law.

 

    	-5-

    	 

    

 

(b)
Each Party shall be solely responsible for any tax imposed on or measured by the net or gross income of such Party or its Affiliates.

 

4.
Regulatory Approvals. Licensor shall be solely responsible for obtaining and maintaining any and all Regulatory Approvals necessary
for the development, manufacture, use, offer for sale, sale or importation of Licensed Products by or on behalf of Licensee or its Affiliates.
Licensor at all times shall comply with all laws, regulations and ordinances, whether federal, state, provincial, county, municipal,
or otherwise, with respect to its and its Affiliates activities with respect to Licensed Products. Licensor will not be responsible for
obtaining and maintaining any and all Regulatory Approvals necessary for the development, manufacture, use, offer for sale, sale or importation
of Licensed Products by or on behalf of any of Licensee’s Sublicensees or their Affiliates.

 

5.
Prosecution and Enforcement of Licensed Patent Rights.

 

5.1
Prosecution. Licensor shall retain the first right to prepare, file, prosecute and maintain the Licensed Patent Rights. Licensor
shall provide Licensee with reasonable opportunities to review and comment on substantive patent prosecution matters with respect to
the Licensed Patent Rights listed on Exhibit A, and shall reasonably consider timely comments thereon provided by Licensee to
Licensor to the extent related to the Field of Use.

 

5.2
Enforcement of Licensed Patent Rights and Licensed Know-How.

 

(a)
Notice. Each Party shall promptly report in writing to the other Party during the Term any (i) known or suspected infringement
of any issued claims within the Licensed Patent Rights by a Third Party, or (ii) any known or suspected misappropriation of any of the
Licensed Know-How by a Third Party. In the event such known or suspected infringement or misappropriation involves the manufacture, sale,
offer for sale, use, or importation in the Territory of a compound or product in the Field of Use that is competitive with any Licensed
Product (“Competitive Infringement”), the reporting Party shall provide the evidence in its possession regarding such
Competitive Infringement to the other Party. Promptly after receipt of a notice of Competitive Infringement, the Parties shall discuss
in good faith the Competitive Infringement and appropriate actions that could be taken to end the Competitive Infringement.

 

(b)
Competitive Infringement. Licensee shall have the first right to initiate a suit or take other appropriate action that it believes
necessary to end any Competitive Infringement, at Licensee’s sole control and expense. If Licensee fails to initiate a suit or
take other appropriate action that it has the initial right to initiate or take to end such Competitive Infringement within sixty (60)
days (or such shorter period specified below in this Section 5.2(b)) after becoming aware of the basis for such suit or action, then
Licensor may, in its discretion, initiate a suit or take other appropriate action that it believes necessary to end such Competitive
Infringement. The sixty (60) day period in the immediately preceding sentence shall be shortened as reasonably necessary to enable Licensor
to initiate a suit or take other appropriate action if, in the absence of such shortening, a loss of rights with respect to such suit
or other action would occur (e.g., if a generic pharmaceutical maker files an abbreviated new drug application or analogous application
for which the reference listed drug is a Licensed Product and, in order to obtain an automatic stay from the applicable Regulatory Authority
with respect to the approval of such application, a patent infringement suit must be brought within a shorter period of time). The Party
filing any such suit or taking any such action shall be responsible for all costs in connection therewith and, therefore, shall control
all decision-making related to any such suit or action.

 

    	-6-

    	 

    

 

(c)
Infringement or Misappropriation other than Competitive Infringement. Licensor shall have the sole right to initiate a suit or
take other appropriate action, at its sole expense and without any duty to account to Licensee therefor, that it believes necessary to
end any infringement or misappropriation of the Licensed Patent Rights or Licensed Know-How other than a Competitive Infringement.

 

(d)
Conduct of Actions. The Party initiating suit or action shall have the sole and exclusive right to select counsel for any suit
initiated by it referred to in Section 5.2(b) above. If required under applicable law in order for the initiating Party to initiate or
maintain such suit or action, the other Party shall join as a party to the suit or action. Such other Party shall offer reasonable assistance
to the initiating Party in connection therewith at no charge to the initiating Party except for reimbursement of reasonable out-of-pocket
expenses incurred in rendering such assistance. The Party filing any such suit or taking any such action shall provide the other Party
with an opportunity to make suggestions and comments regarding such suit or action. Thereafter, the Party filing any such suit or taking
any such action shall, to the extent permitted by applicable law, keep the other Party promptly informed, and shall from time to time
consult with such other Party regarding the status of any such suit or action and shall provide such other Party with copies of all material
documents (i.e., complaints, answers, counterclaims, material motions, orders of the court, memoranda of law and legal briefs, interrogatory
responses, depositions, material pre-trial filings, expert reports, affidavits filed in court, transcripts of hearings and trial testimony,
trial exhibits and notices of appeal) filed in, or otherwise relating to, such suit or action. The Party not initiating such suit or
action shall cooperate with the Party initiating such suit or action to the extent reasonably requested, and shall have the right to
participate and be represented in any such suit by its own counsel at its own expense.

 

(e)
Recoveries. With respect to any suit or action to protect Licensed Patent Rights or Licensed Know-How referred to in Section 5.2(b)
above, any recovery obtained as a result of any such proceeding, by settlement or otherwise, shall be applied in the following order
of priority:

 

(i)
first, the Party initiating the suit or action with respect to Licensed Patent Rights or Licensed Know-How shall be reimbursed for all
out-of-pocket costs and expenses in connection with such proceeding paid by such Party and not otherwise recovered; and

 

(ii)
second, any remainder shall be paid fifty percent (50%) to each Party.

 

6.
Confidentiality

 

6.1
Confidential Information. All Confidential Information disclosed by a Party to the other Party during the Term shall not be used
by the receiving Party except in connection with the activities contemplated by this Agreement, shall be maintained in confidence by
the receiving Party and shall not otherwise be disclosed by the receiving Party to any other Person, firm, or agency, governmental or
private, without the prior written consent of the disclosing Party, except to the extent that the Confidential Information:

 

(a)
was known or used by the receiving Party prior to its date of disclosure to the receiving Party;

 

    	-7-

    	 

    

 

(b)
either before or after the date of the disclosure to the receiving Party is lawfully disclosed to the receiving Party by sources other
than the disclosing Party rightfully in possession of the Confidential Information;

 

(c)
either before or after the date of the disclosure to the receiving Party becomes published or generally known to the public through no
fault or omission on the part of the receiving Party;

 

(d)
is independently developed by or for the receiving Party without reference to or reliance upon the Confidential Information; or

 

(e)
is required to be disclosed by the receiving Party to comply with applicable laws or regulations, to defend or prosecute litigation or
to comply with legal process, provided that the receiving Party provides prior written notice of such disclosure to the disclosing Party
to the extent permissible, only discloses Confidential Information of the other Party to the extent necessary for such legal compliance
or litigation purpose, and seeks a protective order, confidential treatment or the like with respect to the Confidential Information
so disclosed.

 

6.2
Employee, Consultant and Advisor Obligations. Licensee and Licensor each agree that such Party and its Affiliates shall provide
Confidential Information received from the other Party only to the receiving Party’s respective employees, consultants and advisors,
and to the employees, consultants and advisors of the receiving Party’s Affiliates and Sublicensees, who have a need to know such
Confidential Information to assist the receiving Party in fulfilling its obligations under this Agreement; provided that Licensee and
Licensor shall each remain responsible for any failure by such Party and its Affiliates’ respective employees, consultants and
advisors to treat such Confidential Information as required under Section 6.1.

 

6.3
Survival. All obligations of confidentiality imposed under this Section 6 shall survive the termination or expiration of this
Agreement and shall expire ten (10) years following such termination or expiration.

 

7.
Structure and Governance. The development and commercialization of the Licensed Products (the “Commercialization”)
and the administration of the projects referenced herein (the “Projects”) shall be administered as follows.

 

7.1
Joint Steering Committee. The administration of the Projects shall be overseen by a Joint Steering Committee (the “JSC”).
The JSC shall be comprised of six members, three from each company: Dr. David Horn, Dr. David Jobes, Dr. JP Gagnon from MABT and Curative
Medical Lead (to be determined), Michael Grace, Ronald Bordens from CUBT. Each member of the JSC shall have one vote for any matter to
come before its consideration; provided, however, that in the event of a draw in the vote, the Chair shall cast the deciding vote. Dr.
Catherine Sohn to be the outside chair of the steering committee.

 

    	-8-

    	 

    

 

7.2
Duties of JSC. The purpose of the JSC is to ensure continued alignment and communication among the parties. The JSC shall perform
the following functions, including, but not limited to the approval of an annual budget, the development of a sales and marketing plan,
the disbursement of all funds, the development and commercialization of the Licensed Products, and the general governance and development
of the Projects. The Parties agree that within thirty (30) days of final execution of this Agreement they will meet and agree on an initial
annual budget to be substantially in concert with the preliminary budget attached hereto, labeled Exhibit B and incorporated by reference
herein. The JSC shall meet no less than quarterly to provide a detailed status report on budget compliance and progress in general. The
JSC shall also agree internally on a mutually agreeable schedule for disbursement of the funds to be spent in the annual budget.

 

7.3
Vacancy of JSC Member. In the event of the withdrawal or resignation of any member of the JSC, the vacancy shall be filled by
the Party who first appointed such Member.

 

8.0
Project Funding. It shall be the sole responsibility of Licensee to raise funding for the development of the Projects and the
Commercialization of the Licensed Products discussed herein, under the direction of the Licensor and overseen by the JSC, as described
above in Section 7 and below in Section 9. ALL OBLIGATIONS OF LICENSOR HEREUNDER SHALL BE CONTINGENT ON LICENSEE’S OBTAINING
CAPITAL TO ACCOMPLISH THE OBJECTIVES SET FORTH HEREIN including a minimum of $10 million within 90 days of the SEC declaring Licensees
S-1 Registration Statement effective. In addition, Licensee will use its best efforts to raise additional funds as guided by JSC’s
best budgetary estimates; provided, however, that the failure of Licensee’s best efforts to raise additional funds shall not constitute
a material breach of this agreement.

 

9.0
Responsibilities of Parties. The following Responsibilities represent the basic framework for the collaboration and may be amended
from time to time and as needed according to the Joint Steering Committee. For clarity, the Licensee’s responsibilities for funding
the collaboration, and for paying for any penalties, fines, fees for failing to meet vendor obligations (Sections 8 and 9.2) shall not
be amended by the JSC and will remain the sole responsibilities of the Licensee. 

 

9.1
Responsibilities of Licensor. The principal responsibilities of Licensor, in addition to issuing the License hereunder shall be
to oversee the development and commercialization of the Licensed Product, including, but not be limited to, the following: (a) the development
of Good Manufacturing Practice for manufacturing the Licensed Product; (b) the completion of non-clinical (GLP) studies to support an
IND filing; and (c) the preparation and filing of an Investigational New Drug application (the “IND”). Additional funding
will be required to complete the necessary clinical trials for FDA approval, for filing of a Biologics License Application (the “BLA”)
for the Licensed Products to the FDA and the marketing of the Licensed Products in the U.S

 

9.2
Responsibilities of Licensee. The responsibilities of Licensee include, but are not limited to: (a) providing the funding per
Section 8; (b) issuing shares of Licensee’s common stock per the schedule on Section 3.2; (c) providing marketing and business
development in mutually agreed upon areas, such as China and the U.S. Military; and (d) working with Licensor to accomplish the goals
of this Agreement. Licensee is responsible for paying any penalties, fines or fees for failing to meet vendor (including but not limited
to contract manufacturers and contract research organizations) obligations due to lack of funding to be provided by Licensee.

 

    	-9-

    	 

    

 

10.
Representations and Warranties

 

10.1
Representations of Authority. Each Party represents and warrants to the other Party that, as of the Effective Date, it has full
right, power and authority to enter into this Agreement and to perform its respective obligations under this Agreement.

 

10.2
Consents. Each Party represents and warrants to the other Party that, as of the Effective Date, all necessary consents, approvals,
Regulatory Approvals and authorizations of all Regulatory Authorities and other Persons required to be obtained by such Party in connection
with execution, delivery and performance of this Agreement have been obtained

 

10.3
No Conflict. Each Party represents and warrants to the other Party that, as of the Effective Date, the execution and delivery
of this Agreement and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement
of applicable laws or regulations and (b) do not conflict with, violate or breach or constitute a default of, or require any consent
under, any contractual obligations of such Party, except such consents as have been obtained as of the Effective Date. In addition, Licensee
represents, warrants and covenants to Licensor that Licensee shall comply with all applicable laws or regulations with respect to the
Agreement or the use of any Licensed Products.

 

10.4
No Warranties. EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF
ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR
NON-INFRINGEMENT. WITHOUT LIMITING THE FOREGOING, LICENSOR DOES NOT MAKE, AND HEREBY DISCLAIMS, ANY REPRESENTATION OR WARRANTY, EXPRESS
OR IMPLIED, REGARDING THE DESIGN, MANUFACTURABILITY, MERCHANTABILITY OR FITNESS FOR ANY PURPOSE OF ANY LICENSED PRODUCT.

 

11.
Indemnification

 

11.1
By Licensee. Licensee agrees to defend Licensor, its Affiliates and its or their respective directors, officers, employees or
agents at Licensee’s cost and expense, and shall indemnify and hold harmless Licensor and its Affiliates and its or their respective
directors, officers, employees or agents, from and against any liabilities, losses, costs, damages, fees or expenses arising out of any
Third Party claim to the extent arising from (i) any breach by Licensee of any of its representations or warranties pursuant to this
Agreement, (ii) the development, manufacture, use, offer for sale, sale or importation of any Licensed Product by or on behalf of Licensee
or any of its Affiliates or (iii) personal injury, property damage or other damage resulting from the development, manufacture, use or
commercialization of a Licensed Product by or on behalf of Licensee or its Affiliates or any of their customers. Licensee will indemnify
Licensor in the event that Licensor incurs, penalties, fines or fees for failing to meet vendor (including but not limited to contract
manufacturers and contract research organizations) obligations due to lack of funding to be provided by Licensee.

 

    	-10-

    	 

    

 

11.2
By Licensor. Licensor agrees to defend Licensee, its Affiliates and its or their respective directors, officers, employees or
agents at Licensor’s cost and expense, and shall indemnify and hold harmless Licensee and its Affiliates and its or their respective
directors, officers, employees or agents, from and against any liabilities, losses, costs, damages, fees or expenses arising out of any
Third Party claim to the extent such Third Party claim arises from (i) any breach by Licensor of any of its representations or warranties
pursuant to this Agreement, (ii) the development, manufacture, use, offer for sale, sale or importation of any Licensed Product by or
on behalf of Licensor or any of its Affiliates or (iii) personal injury, property damage or other damage resulting from the development,
manufacture, use or commercialization of a Licensed Product by or on behalf of Licensor or its Affiliates or any of their customers.

 

11.3
Procedures. A Person entitled to indemnification under this Section 11 (an “Indemnified Party”) shall give prompt
written notification to the Party from whom indemnification is sought (the “Indemnifying Party”) of any claim for which indemnification
is sough under this Agreement. Within thirty (30) days after delivery of such notification, the Indemnifying Party may, upon written
notice thereof to the Indemnified Party, assume control of the defense of such claim with counsel reasonably satisfactory to the Indemnified
Party. If the Indemnifying Party does not assume control of such defense, the Indemnified Party shall control such defense. The Party
not controlling such defense may participate therein at its own expense; provided that the Indemnified Party shall have the right to
retain its own counsel, at the expense of the Indemnifying Party, if representation of such Indemnified Party by the counsel retained
by the Indemnifying Party would be inappropriate because of actual or potential differences in the interests of such Indemnified Party
and any other party represented by such counsel. The Indemnified Party shall not agree to any settlement of such claim without the prior
written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned.

 

11.4
Insurance. Licensee and Licensor shall have and maintain such types and amounts of insurance covering its development, manufacture,
use, offer for sale, sale and importation of License Products as is (i) normal and customary in the pharmaceutical products industries
generally for parties similarly situated and (ii) otherwise required by applicable law. Upon request by Licensor, Licensee shall provide
to Licensor evidence of its insurance coverage. The insurance policies shall be under an occurrence form, but if only a claims-made form
is available to Licensee or Licensor, then both shall continue to maintain such insurance after the expiration or termination of this
Agreement for a period of five (5) years.

 

12.
Term and Termination. Licensor shall have the right to terminate this agreement as of January 31, 2022 if Licensee shall have
failed to provide $10,000,000 to Licensor by January 31, 2022, unless an extension is agreed to by both Parties.

 

12.1
Term. This Agreement shall become effective as of the Effective Date, may be terminated as set forth in this Section 12, and otherwise
shall remain in effect for so long as the Licensed Products are sold.

 

    	-11-

    	 

    

 

12.2
Termination for Material Breach. Upon any material breach of this Agreement by either Party, the other Party may terminate this
Agreement by providing sixty (60) days’ written notice to the breaching Party, specifying the material breach. The termination
shall become effective at the end of the sixty (60) day period unless the breaching Party cures such breach during such sixty (60) day
period.

 

12.3
Effects of Termination. Upon termination of this Agreement prior to the end of the Term, as a result of the material breach of
CUBT (but not upon expiration of this Agreement at the end of the Term):

 

(a)
Licensee shall immediately assign and transfer to Licensor all Licensed Product-specific trademarks used in association with Licensed
Product(s) or interests therein;

 

(b)
Licensee shall immediately assign and transfer to Licensor all regulatory documents if any filed by Licensee, its representatives or
manufacturers to the extent relating to IMT504 or Licensed Product(s);

 

(c)
Licensee shall immediately assign and transfer to Licensor all regulatory approvals for Licensed Product(s) held in the name of Licensee
or any of its subsidiaries in each country in the Territory; and

 

(d)
The License granted to Licensor in Section 2.5 shall expand to include the Field of Use.

 

Upon
termination of this Agreement as the result of a material uncured breach by Licensor, which breach remains uncured for 30 days after
notice from Licensee, Licensor shall have the same obligations to Licensee as provided for in 12.3 (a), (b), (c) and (d) directly above;
and shall reaffirm the License granted in sections 2.1 and 2.5 above for the Field of Use as stated above. Licensee shall take over the
development of the Licensed Product. The JSC shall be dissolved. All other terms and conditions shall survive as written.

 

12.4
Survival. The following provisions shall survive the expiration or termination of this Agreement in accordance with their terms:
Sections 2.5, 3.2, 3.3, 3.4, 3.5, 6, 10.4, 11, 12.3, 12.4 and 13.

 

13.
Miscellaneous Provisions

 

13.1
Governing Law. This Agreement and all disputes arising out of or related to this Agreement shall be construed and the respective
rights of the Parties determined in accordance with the laws of the Commonwealth of Pennsylvania, notwithstanding the provisions thereof
governing conflicts of laws.

 

    	-12-

    	 

    

 

13.2
Notice. Any notices required or permitted by this Agreement shall be in writing, shall specifically refer to this Agreement, and
shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered
or certified mail, postage prepaid, return receipt requested, to the following address or facsimile number of the parties:

 

	If to Licensor:
	 	 
	 	Mid-Atlantic
    BioTherapeutics, Inc.
	 	Attn:
    Dr. David Horn
	 	3805
    Old Easton Road
	 	Doylestown,
    PA 18902
	 	215-266-2301
	 	dhorn@mid-atlanticbio.com
	 	 
	If to Licensee:
	 	 
	 	Curative
    Biotechnology, Inc
	 	Attn:
    I Richard Garr
	 	1825
    NW Corporate Blvd., Suite 101
	 	Boca
    Raton, FL 33431
	 	561-418-7725
	 	irgarr@curativebiotech.com

 

All
notices under this Agreement shall be deemed effective upon receipt. A party may change its contact information immediately upon written
notice to the other party in the manner provided in this Section.

 

13.3
Assignment. This Agreement is personal to Licensee and no rights or obligations may be assigned by Licensee without the prior
written consent of Licensor, except any Party may assign this Agreement to an Affiliate of such Party or in connection with the sale
or transfer of all or substantially all of the business or assets of such Party relating to the subject matter of this Agreement.

 

13.4
Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to its subject matter and supersedes
all prior agreements or understandings between the Parties relating to its subject matter.

 

13.5
Amendment and Waiver. This Agreement may be amended, supplemented, or otherwise modified only by means of a written instrument
signed by both Parties. Any waiver of any right or failure to act in a specific instance shall related only to such instance and shall
not be construed as an agreement to waive any right or fail to act in any other instance, whether or not similar.

 

13.6
Severability. In the event that any provision of this Agreement shall be held invalid or unenforceable for any reason, such invalidity
or unenforceability shall not affect any other provision of this Agreement. The Parties shall consult one another and use reasonable
efforts to agree upon a valid and enforceable provision that is a reasonable substitute for the invalid or unenforceable provision.

 

    	-13-

    	 

    

 

13.7
EXCLUSION OF CONSEQUENTIAL DAMAGES. OTHER THAN IN CONNECTION WITH A PARTY’S INDEMNIFICATION OBLIGATIONS HEREUNDER AS TO
THIRD PARTY CLAIMS IN ACCORDANCE WITH SECTION 11, NEITHER PARTY HERETO WILL BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY,
PUNITIVE OR OTHER INDIRECT DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, OR FOR LOST PROFITS ARISING
FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.

 

13.8
Counterparts. This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, shall
be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument.

 

13.9
Force Majeure. Neither party will be responsible for delays resulting from causes beyond the reasonable control of such party,
which may include without limitation fire, explosion, flood, war, strike or riot, provided that the nonperforming party uses commercially
reasonable efforts to avoid or remove such causes of nonperformance and continues performance under this Agreement with reasonable dispatch
whenever such causes are removed.

 

13.10
Dispute Resolution.

 

(a)
Alternative Dispute Resolution. Any dispute arising out of or relating to this Agreement shall be resolved through binding arbitration
as follows:

 

(i)
A Party may submit such dispute to arbitration by notifying the other Party, in writing, of such dispute. Within thirty (30) days after
receipt of such notice, the Parties shall designate in writing a single arbitrator to resolve the dispute; provided, however, that if
the Parties cannot agree on an arbitrator within such 30-day period, the arbitrator shall be selected by the Philadelphia, Pennsylvania
office of the American Arbitration Association (the “AAA”). The arbitrator shall not be an Affiliate, employee, consultant,
officer, director or stockholder of any Party.

 

(ii)
Within thirty (30) days after the designation of the arbitrator, the arbitrator and the Parties shall meet, at which time the Parties
shall be required to set forth in writing all disputed issues and a proposed ruling on the merits of each such issue.

 

(iii)
The arbitrator shall set a date for a hearing, which shall be no later than forty-five (45) days after the submission of written proposals
pursuant to Section 13.10(a)(ii), to discuss each of the issues identified by the Parties. The Parties shall have the right to be represented
by counsel. Except as provided herein, the arbitration shall be governed by the Commercial Arbitration Rules of the AAA; provided, however,
that the Federal Rules of Evidence shall apply with regard to the admissibility of evidence and the arbitration shall be conducted by
a single arbitrator. The arbitration shall be in English.

 

(iv)
The arbitrator shall use his or her best efforts to rule on each disputed issue within thirty (30) days after the completion of the hearings
described in Section 13.10(a)(iii). The determination of the arbitrator as to the resolution of any dispute shall be binding and conclusive
upon all Parties. All rulings of the arbitrator shall be in writing and shall be delivered to the Parties.

 

(v)
The attorneys’ fees of the Parties in any arbitration, fees of the arbitrator, and costs and expenses of the arbitration shall
be borne by the Parties as determined by the arbitrator.

 

(vi)
Any arbitration pursuant to this Section 13.10 shall be conducted in Philadelphia, Pennsylvania. Any arbitration award may be entered
in and enforced by any court of competent jurisdiction.

 

(b)
No Limitation. Nothing in Section 13.10 shall be construed as limiting in any way the right of a Party to seek an injunction or
other equitable relief with respect to any actual or threatened breach of this Agreement or to bring an action in aid of arbitration.
Should any Party seek an injunction or other equitable relief, or bring an action in aid of arbitration, then for purposes of determining
whether to grant such injunction or other equitable relief, or whether to issue any order in aid of arbitration, the dispute underlying
the request for such injunction or other equitable relief, or action in aid of arbitration, may be heard by the court in which such action
or proceeding is brought.

 

    	-14-

    	 

    

 

IN
WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

 

	Mid-Atlantic
    BioTherapeutics, Inc.	 	Curative
    Biotechnology, Inc.
	 	 	 	 	              
	By:	 /s/
    David Horn 	 	By:	 /s/ Richard Garr 
	 	 	 	 	 
	Name:
    	David
    Horn, M.D.	 	Name:	 I Richard Garr 
	 	 	 	 	 
	Title:
    	CEO	 	Title:	 CEO 
	 	 	 	 	 
	David Horn, LLC	 	 	 
	 	 	 	 	 
	By:	 /s/
    David Horn 	 	 	 
	 	 	 	 	 
	Name:
    	David
    Horn, M.D.	 	 	 
	 	 	 	 	 
	Title:
    	Principal	 	 	 

 

    	-15-

    	 

    

 

Exhibit
A

Licensed
Patent Rights

 

PATENT
PORTFOLIO SUMMARY CHART

Updated
October 29, 2019

 

Title:
Immunostimulatory Oligonucleotides and Uses Thereof

 

NOTE:
ANY SUBLICENSE TO CHINA OR ANY OTHER TERRITORY NOT INCLUDED IN THE TABLE BELOW, OR ANY COMPANY DOMESTICATED IN CHINA OR ANY OTHER TERRITORY
NOT INCLUDED IN THE TABLE BELOW, WILL REQUIRE PRIOR WRITTEN APPROVAL OF LICENSOR

 

	Country	 	Appl.
    No./ Patent No.	 	Filing
    Date/ Issue Date	 	Recorded
    Owner	 	Status	 	Next
    Action Due	 	Comments
	U.S.	 	10/309,775

    7,038,029
	 	04-Dec-2002

    02-May-2006
	 	David
    Horn, LLC	 	Issued	 	No
    further action; All maintenance fees have been paid	 	Standard
    expiration Apr. 1, 2023 (+ 118 day PTA)
	U.S.	 	11/178,086

    7,381,807
	 	08-Jul-2005

    03-Jun-2008
	 	David
    Horn, LLC	 	Issued	 	Third
    and final maintenance fee to be paid before Jun. 3, 2020 (Payment window opened on Jun. 3, 2019 and surcharge period runs from Dec.
    4, 2019 to Jun. 3, 2020)	 	Standard
    expiration Nov. 25, 2023 (+ 356 days PTA)
	U.S.	 	12/111,006
    7,943,316	 	28-Apr-2008
    17-May-2011	 	David
    Horn, LLC	 	Issued	 	Third
    and final maintenance fee to be paid before May 5, 2023 (Payment window opens on May 17, 2022 and surcharge period runs from November
    18, 2022 to May 17, 2023)	 	Standard
    expiration Dec. 4, 2022 (+ 0 days PTA)
	U.S.	 	13/099,778
    8,871,436	 	03-May-2011
    28-Oct-2014	 	David
    Horn, LLC 	 	Issued	 	Second
    maintenance fee to be paid before Oct 28, 2022 (Payment window opens on Oct 28, 2021, and surcharge period runs from Apr. 29, 2022
    to Oct 28, 2022)	 	Standard
    Expiration June 28, 2024 (+ 572 days PTA)
	Australia	 	2003250334

    2003250334
	 	30-May-2003

    25-Nov-2004
	 	David
    Horn, LLC	 	Issued	 	May
    30, 2020 – Renewal fees due	 	 

 

    	-16-

    	 

    

 

	Country	 	Appl.
    No./ Patent No.	 	Filing
    Date/ Issue Date	 	Recorded
    Owner	 	Status	 	Next
    Action Due	 	Comments
	European
    Patent Convention	 	03755959.8

    1511845
	 	30-May-2003

    09-Mar-2005
	 	David
    Horn, LLC	 	Issued	 	May
    30, 2020 – annuities due in:

     

    BE
    Belgium

    CH/LI
    Switzerland/ Liechtenstein

    DE
    Germany

    DK
    Denmark

    FI
    Finland FR France GB United Kingdom GR Greece HU Hungary IE Ireland NL Netherlands PT Portugal SE Sweden TR Turkey CY Cyprus ES Spain
    IT Italy

     

     
	 	Status
    of each validated country:

     

    Confirmed
    2019 annuity paid in (next annuity due 2020):

    BE
    Belgium

    CH/LI
    Switzerland/ Liechtenstein

    DE
    Germany DK Denmark ES Spain FI Finland FR France GR Greece HU Hungary IE Ireland IT Italy PT Portugal SE Sweden TR Turkey CY Cyprus

     

    Status
    of current validated country:

     

    2020
    annuity paid:

     

    DE
    Germany

     

    ES
    Spain

     

    FR
    France

     

    IT
    Italy

     

    GB
    Great Britain

     

     

	India	 	3773/DLNP72004
    252038	 	29-Nov-2004
    23-Apr-2012	 	David
    Horn, LLC	 	Issued	 	May
    30, 2020 – Next annuity payment due	 	Statement
    of working will also be due May 30, 2020
	Mexico	 	2004/011937	 	30-Nov-2004	 	David
    Horn, LLC	 	Issued	 	May
    30, 2020 – Next annuity payment due	 	 
	New
    Zealand	 	20030536962
    536962	 	25-Nov-2004
    11-Jan-2007	 	David
    Horn, LLC	 	Issued	 	May
    30, 2020 – renewal fees due 	 	 

 

	U.S.
    Provisional Application No. 63/107,641

 

	Title:
    	IMMUNOSTIMULATORY
    OLIGONUCLEOTIDES FOR
	 	THE
    PREVENTION AND TREATMENT OF COVID-19
	 	 
	Filed:	October
    30, 2020

 

	Troutman
    Pepper Ref. No.: 258157.000100 

 

    	-17-

    	 

    

 

Exhibit
B

Preliminary
COVID-19 Vaccine Development Budget Estimates

 

	Budget Item	 	Months 1-3 (Year 1)	 	 	Months 4-6 (Year 1)	 	 	Months 7-9 (Year 1)	 	 	Months 10-12 (Year 1)	 	 	Months 1-3 (Year 2)	 	 	Months 4-6 (Year 2)	 	 	Months 7-9 (Year 2)	 	 	Months 10-12 (Year 2)	 	 	Totals	 
	CURRENT SCENARIO	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	GMP mfg	 	$	7,765,000	 	 	$	780,000	 	 	$	1,630,000	 	 	$	2,100,000	 	 	$	705,000	 	 	$	750,000	 	 	$	0	 	 	$	0	 	 	$	13,730,000	 
	Preclinical/IND studies	 	$	0	 	 	$	50,000	 	 	$	1,000,000	 	 	$	250,000	 	 	$	500,000	 	 	$	500,000	 	 	$	500,000	 	 	$	500,000	 	 	$	3,300,000	 
	Regulatory	 	$	100,000	 	 	$	100,000	 	 	$	100,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	550,000	 
	Personnel	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	1,200,000	 
	G&A	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	400,000	 
	License Fees	 	$	400,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	400,000	 
	 	 	$	8,465,000	 	 	$	1,130,000	 	 	$	2,930,000	 	 	$	2,600,000	 	 	$	1,455,000	 	 	$	1,500,000	 	 	$	750,000	 	 	$	750,000	 	 	$	19,580,000	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Overall Total:	 	 	$	19,580,000	 
	 	 	 	 	 	 	 	1-year cumulative total	 	 	$	15,125,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	9-month cumulative total	 	 	$	12,525,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

Notes:

 

1)
The Halix estimates for GMP mfg were in Euros so we converted at the current (27SEP21) ratio of 0.85 Euro/Dollar and rounded up

2)
The first three months in Year 1 include a 50% start up payment for GMP manufacturing

3)
Preclinical/IND studies will take 10-12 months so we need to initiate those in Year 1

 

	OPTIMISTIC SCENARIO	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	GMP mfg	 	$	6,765,000	 	 	$	780,000	 	 	$	1,630,000	 	 	$	2,100,000	 	 	$	705,000	 	 	$	750,000	 	 	$	0	 	 	$	0	 	 	$	12,730,000	 
	Preclinical/IND studies	 	$	0	 	 	$	50,000	 	 	$	500,000	 	 	$	250,000	 	 	$	500,000	 	 	$	500,000	 	 	$	500,000	 	 	$	500,000	 	 	$	2,800,000	 
	Regulatory	 	$	100,000	 	 	$	100,000	 	 	$	100,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	550,000	 
	Personnel	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	150,000	 	 	$	1,200,000	 
	G&A	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	50,000	 	 	$	400,000	 
	License Fees	 	$	250,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	$	250,000	 	 	$	500,000	 
	 	 	$	7,315,000	 	 	$	1,130,000	 	 	$	2,430,000	 	 	$	2,600,000	 	 	$	1,455,000	 	 	$	1,500,000	 	 	$	750,000	 	 	$	1,000,000	 	 	$	18,180,000	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	Overall Total:	 	 	$	18,180,000	 
	 	 	 	 	 	 	 	1-year cumulative total	 	 	$	13,475,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	9-month cumulative total	 	 	$	10,875,000	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

Notes:

1)
Use of Rodent species vs. NHP model

  

    	-18-Exhibit
10.12

 

PUBLIC
HEALTH SERVICE

 

PATENT
LICENSE AGREEMENT – EXCLUSIVE EVALUATION OPTION LICENSE

 

This
Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”)
Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for
Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are
agencies of the PHS within the Department of Health and Human Services (“HHS”).

 

This
Cover Page identifies the Parties to this Agreement:

 

The
U.S. Department of Health and Human Services, as represented by

 

National
Cancer Institute

 

an
Institute or Center (hereinafter referred to as the “IC”) of the

 

NIH

 

and

 

Connectyx
Technologies Holdings Group

 

hereinafter
referred to as the “Licensee”,

 

having
offices at 1825 NW Corporate Boulevard, Suite 110, Boco Raton, FL 33431,

 

created
and operating under the laws of Florida.

 

Tax
ID No.: 26-1412177

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 1 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

For
the IC internal use only:

 

License
Number:

 

License
Application Number: A-449-2020

 

Serial
Number(s) of Licensed Patent(s) or Patent Application(s):

 

HHS
Ref. No. E-221-2015-0

 

Entitled:
“ANTIBODY - DRUG CONJUGATES FOR TARGETING CD56 - POSITIVE TUMORS”

 

Inventors:
Dimiter S. Dimitrov, Yang Feng, and Zhongyu Zhu (NCI), and John M. Maris, Robyn Tovah Sussman (Children’s Hospital of Philadelphia
“CHOP”).

 

		I.	U.S.
                                            Provisional Patent Application No. 62/119,707 filed July 31, 2015. HHS Ref No. E-221-2015-0-US-01

 

		II.	PCT
                                            Application No. PCT/US2016/044777 filed 07/29/2016. HHS Ref. No. E-221-2015-0-PCT-02

 

		III.	US
                                            Patent No. 10,548,987 issued February 02, 2020 (Patent Application No. 15/747,620 filed January
                                            25, 2018). HHS Ref. No. E-221-2015-0-US-03.

 

Cooperative
Research and Development Agreement (CRADA) Number (if a subject invention): NA

 

Additional
Remarks:

 

Public
Benefit(s): Development of an anti-CD56 antibody drug conjugate for the treatment of glioblastoma.

 

This
Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement,
a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties),
Appendix D (Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Royalty Payment Option), and Appendix
G (Shipping Information).

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 2 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

The
IC and the Licensee agree as follows:

 

	1.	BACKGROUND

 

		1.1	In
                                            the course of conducting biomedical and behavioral research, the IC investigators
                                            made inventions that may have commercial applicability.

 

		1.2	By
                                            assignment of rights from IC employees and other inventors, HHS, on behalf
                                            of the Government, owns intellectual property rights claimed in any United States
                                            or foreign patent applications or patents corresponding to the assigned inventions. HHS
                                            also owns any tangible embodiments of these inventions actually reduced to practice by
                                            the IC.

 

		1.3	The
                                            Secretary of HHS has delegated to the IC the authority to enter into this Agreement
                                            for the licensing of rights to these inventions.

 

		1.4	The
                                            IC desires to transfer these inventions to the private sector through commercialization
                                            licenses to facilitate the commercial development of products and processes for public use
                                            and benefit.

 

		1.5	The
                                            Licensee desires to acquire commercialization rights to certain of these inventions
                                            in order to develop processes, methods, or marketable products for public use and benefit.

 

	2.	DEFINITIONS

 

		2.1	“Affiliate(s)”
                                            means a corporation or other business entity, which directly or indirectly is controlled
                                            by or controls, or is under common control with the Licensee. For this purpose, the
                                            term “control” shall mean ownership of more than fifty percent (50%) of the voting
                                            stock or other ownership interest of the corporation or other business entity, or the power
                                            to elect or appoint more than fifty percent (50%) of the members of the governing body of
                                            the corporation or other business entity.

 

		2.2	“Benchmarks”
                                            mean the performance milestones that are set forth in Appendix D.

 

		2.3	“Commercial
                                            Evaluation Plan” means the written evaluation plan attached as Appendix E, submitted
                                            to the IC by the Licensee that describes plans for initial development of the
                                            Licensed Products or Licensed Processes within the scope of the Licensed
                                            Patent Rights and the Licensed Field(s) of Use under the terms of this Agreement.

 

		2.4	“Commercial
                                            Development Plan” means a written commercialization plan, to be submitted to the
                                            IC upon Licensee’s exercise of the option under the terms of this Agreement,
                                            that describes plans for complete development and achievement of “practical application”,
                                            as defined in 35 U.S.C, § 201(f), of subject matter relevant to the Licensed Patent
                                            Rights.

 

		2.5	“Commercial
                                            Purpose” means the sale, lease, license, distribution in lieu of purchase, or any
                                            other transfer of the Licensed Products, excluding transfers to contractors or non-profit
                                            collaborators for internal evaluation or internal research. Commercial Purpose shall
                                            also include uses of the Licensed Products to perform contract research, to screen
                                            libraries, to produce or manufacture products for general sale, or to conduct activities
                                            that result in any direct or indirect sale, lease, license, or transfer of the Licensed
                                            Products.

 

		2.6	“CRADA”
                                            means a Cooperative Research and Development Agreement.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 3 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

		2.7	“Effective
                                            Date” means the date when the last party to sign has executed this Agreement.

 

		2.8	“Extraordinary
                                            Expenditures” means expenses arising from actions beyond the norms of typical preparation,
                                            filing, and prosecution of the Licensed Patent Rights, including, without limitation,
                                            interferences, reexaminations, reissues, oppositions, and defense.

 

		2.9	“FDA”
                                            means the Food and Drug Administration.

 

		2.10	“Government”
                                            means the Government of the United States of America.

 

		2.11	“Licensed
                                            Fields of Use” means the fields of use identified in Appendix B.

 

		2.12	“Licensed
                                            Patent Rights” shall mean:

 

	 	(a)	Patent
    applications (including provisional patent applications and PCT patent applications) or patents listed in Appendix A, all divisions
    and continuations of these applications, all patents issuing from these applications, divisions, and continuations, and any reissues,
    reexaminations, and extensions of these patents;
	 	 	 
	 	(b)	to
    the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.12(a):

 

	 	(i)	continuations-in-part
    of 2.12(a);
	 	 	 
	 	(ii)	all
    divisions and continuations of these continuations-in-part;
	 	 	 
	 	(iii)	all
    patents issuing from these continuations-in-part, divisions, and continuations;
	 	 	 
	 	(iv)	priority
    patent application(s) of 2.12(a); and
	 	 	 
	 	(v)	any
    reissues, reexaminations, and extensions of these patents;

 

	 	(c)	to
    the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.12(a): all counterpart
    foreign and U.S. patent applications and patents to 2.12(a) and 2.12(b), including those listed in Appendix A; and
	 	 	 
	 	(d)	Licensed
    Patent Rights shall not include 2.12(b) or 2.12(c) to the extent that they contain one or more claims directed to new
    matter which is not the subject matter disclosed in 2.12(a).

 

		2.13	“Licensed
                                            Processes” means processes which, in the course of being practiced, would be within
                                            the scope of one or more claims of the Licensed Patent Rights that have not been held
                                            unpatentable, invalid or unenforceable by an unappealed or unappealable judgment of a court
                                            of competent jurisdiction.

 

		2.14	“Licensed
                                            Products” means tangible materials which, in the course of manufacture, use, sale,
                                            or importation, would be within the scope of one or more claims of the Licensed Patent
                                            Rights that have not been held unpatentable, invalid or unenforceable by an unappealed
                                            or unappealable judgment of a court of competent jurisdiction.

 

		2.15	“Licensed
                                            Territory” means the geographical area identified in Appendix B.

 

		2.16	“Materials”
                                            means tangible materials provided to the Licensee by IC, as available,
                                            including all progeny, subclones and unmodified derivatives thereof, if applicable,
                                            as described in Appendix A.

 

		2.17	“Net
                                            Sales” means the total gross receipts for sales of Licensed Products or
                                            practice of Licensed Processes by or on behalf of the Licensee or its sublicensees,
                                            and from leasing, renting, or otherwise making the Licensed Products available to
                                            others without sale or other dispositions, whether invoiced or not, less returns and allowances,
                                            packing costs, insurance costs, freight out, taxes or excise duties imposed on the transaction
                                            (if separately invoiced), and wholesaler and cash discounts in amounts customary in the trade
                                            to the extent actually granted. No deductions shall be made for commissions paid to individuals,
                                            whether they are with independent sales agencies or regularly employed by the Licensee,
                                            or sublicensees, and on its payroll, or for the cost of collections.

 

		2.18	“Practical
                                            Application” means to manufacture in the case of a composition or product, to practice
                                            in the case of a process or method, or to operate in the case of a machine or system; and
                                            in each case, under these conditions as to establish that the invention is being utilized
                                            and that its benefits are to the extent permitted by law or Government regulations
                                            available to the public on reasonable terms.

 

		2.19	“Research
                                            License” means a nontransferable, nonexclusive license to make and to use the Licensed
                                            Products or the Licensed Processes as defined by the Licensed Patent Rights
                                            for purposes of research and not for purposes of commercial manufacture or distribution
                                            or in lieu of purchase.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 4 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

		2.20	“Third
                                            Party Contractor(s)” means a third-party organization, acting with, on behalf and
                                            for the benefit of Licensee limited to the development of the Licensed Products
                                            for consideration. 

 

	3.	GRANT
                                            OF RIGHTS

 

		3.1	The
                                            IC hereby grants to the Licensee an exclusive evaluation license, for evaluation
                                            purposes only, to make and use, but not to sell, the Materials or Licensed
                                            Products or inventions within the scope of the Licensed Patent Rights within the
                                            Licensed Fields of Use and in the Licensed Territory, and to practice Licensed
                                            Processes within the Licensed Fields of Use and in the Licensed Territory.
                                            The rights provided herein are provided for the evaluation of commercial applications only
                                            and not for a Commercial Purpose.

 

		3.2	The
                                            Licensee is entitled to transfer Materials to Third-Party Contractor(s)
                                            and to authorize its Third-Party Contractor(s) to make, have made and to use,
                                            but not to sell Materials and Licensed Products on Licensee’s
                                            behalf solely in the Licensed Fields of Use and in the Licensed Territory.
                                            Licensee shall ensure that such Third-Party Contractors comply with the terms
                                            and obligations of this Agreement with respect to their use of the Materials and/or
                                            the Licensed Products.

 

		3.3	To
                                            exercise the exclusive option, Licensee must submit a written notice to the IC
                                            one (1) month prior to the termination or expiration of this Agreement. The written
                                            notice must include an updated License Application and a Commercial Development Plan and
                                            will initiate a negotiation period that expires three (3) months after the exercise of the
                                            option. In the absence of Licensee’s exercise of the option to an exclusive
                                            license, the IC will be free to license the Licensed Patent Rights within or
                                            outside the Licensed Fields of Use to others. These time periods may be extended at
                                            the sole discretion of IC upon written request and a showing of good cause by Licensee.
                                            Licensee agrees that the continued use of the Materials, Licensed Products,
                                            or Licensed Patent Rights after expiration or termination of this Agreement
                                            will occur only pursuant to a separate license agreement. The continued use of the Materials,
                                            Licensed Products, or Licensed Patent Rights after expiration or termination
                                            of this Agreement without the exercise of the exclusive option or the execution of
                                            a separate license agreement granting such rights will be considered a material breach of
                                            this Agreement.

 

		3.4	For
                                            the avoidance of doubt, the Licensed Fields of Use provided in this Agreement
                                            is only applicable for the Exclusive Evaluation Option License. The licensed field of use
                                            for any subsequent Exclusive Commercial Patent License Agreement shall be commensurate in
                                            scope with the Commercial Development Plan provided at the time of negotiation of
                                            any such license and subject to IC’s review and approval, and the Licensee
                                            acknowledges that it may be narrowed for the subsequent Exclusive Commcercial Patent
                                            License Agreement.

 

		3.5	This
                                            Agreement confers no license or rights by implication, estoppel, or otherwise under
                                            any patent applications or patents of the IC other than the Licensed Patent Rights
                                            regardless of whether these patents are dominant or subordinate to the Licensed Patent
                                            Rights.

 

		3.6	The
                                            Licensee represents that it and Third Party Contractor(s) have the facilities,
                                            personnel, and expertise to evaluate the commercial applications of the Materials, Licensed
                                            Products, Licensed Processes, or inventions within the scope of the Licensed
                                            Patent Rights within the Licensed Fields of Use as outlined in the Commercial
                                            Evaluation Plan.

 

	4.	SUBLICENSING

 

		4.1	Under
                                            this Agreement, sublicensing is not permitted.

 

		5.	STATUTORY
                                            AND NIH REQUIREMENTS AND RESERVED GOVERNMENT RIGHTS

 

		5.1	The
                                            IC reserves on behalf of the Government an irrevocable, nonexclusive, nontransferable,
                                            royalty-free license for the practice of all inventions licensed under the Licensed Patent
                                            Rights throughout the world by or on behalf of the Government and on behalf of
                                            any foreign government or international organization pursuant to any existing or future treaty
                                            or agreement to which the Government is a signatory.

 

		5.2	The
                                            Licensee acknowledges that the IC may enter into future CRADAs under
                                            the Federal Technology Transfer Act of 1986 that relate to the subject matter of this
                                            Agreement. The Licensee agrees not to unreasonably deny requests for a Research
                                            License from future collaborators with the IC when acquiring these rights is necessary
                                            in order to make a CRADA project feasible. The Licensee may request an opportunity
                                            to join as a party to the proposed CRADA.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 5 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

		5.3	The
                                            IC reserves the right to grant Research Licenses directly or to require the
                                            Licensee to grant Research Licenses on reasonable terms. The purpose of these
                                            Research Licenses is to encourage basic research, whether conducted at an academic
                                            or corporate facility. To safeguard the Licensed Patent Rights, however, the IC
                                            shall consult with the Licensee before granting to commercial entities a Research
                                            License or providing to them research samples of materials made through the Licensed
                                            Processes.

 

		5.4	If
                                            Licensee executes an exclusive or non-exclusive commercialization license after the
                                            expiration of this Agreement, as per in Paragraph 3.3, Licensee agrees that
                                            products used or sold in the United States embodying the Licensed Products or produced
                                            through use of the Licensed Processes shall be manufactured substantially in the United
                                            States, unless a written waiver is obtained in advance from the IC.

 

		6.	ROYALTIES
                                            AND REIMBURSEMENT

 

		6.1	In
                                            consideration of the grant in Paragraph 3.1, the Licensee agrees to pay the IC
                                            a non-creditable, non-refundable, license issue royalty as set forth in Appendix C within
                                            sixty (60) days of the Effective Date of this Agreement, and a second non-creditable,
                                            non-refundable, patent reimbursement royalty on the one-year anniversary of the Effective
                                            Date of this Agreement. These royalties shall be paid in U.S. dollars in accordance
                                            with the payment schedule listed in Appendix C. For conversion of foreign currency to U.S.
                                            dollars, the conversion rate shall be the New York foreign exchange rate quoted in The
                                            Wall Street Journal on the day that the payment is due. Any loss of exchange, value,
                                            taxes, or other expenses incurred in the transfer or conversion to U.S. dollars shall be
                                            paid entirely by the Licensee.

 

		6.2	As
                                            described below in Paragraph 7.2, when the IC has approved Licensee’s
                                            request for additional patent filings or additional prosecution actions beyond those taken
                                            by the IC, the Licensee shall be wholly responsible to the law firm employed
                                            by the IC for direct payment of all expenses resulting from such approved requests.
                                            In this event, the IC and not the Licensee shall be the client of the law firm,
                                            and the Licensee acknowledges that the IC will not provide privileged attorney-client
                                            communications or work product to the Licensee.

 

	7.	PATENT
                                            FILING, PROSECUTION, AND MAINTENANCE

 

		7.1	Except
                                            as otherwise provided in this Article 7, the IC agrees to take responsibility for
                                            the prosecution and maintenance of the patent applications or patents listed in Appendix
                                            A, which are the Licensed Patent Rights on the Effective Date of this Agreement.
                                            If the IC anticipates the possibility of any Extraordinary Expenditures, the
                                            IC will send prior written notice to Licensee, and the IC will not be
                                            required to incur such Extraordinary Expenditures. At the IC’s sole option,
                                            the IC may elect to abandon the patent rights associated with such Extraordinary
                                            Expenditures. In such event, the Licensee may request that the IC incur
                                            such Extraordinary Expenditures at the Licensee’s expense, which shall
                                            require approval by IC. In addition, the Licensee may request further prosecution
                                            actions beyond those taken by the IC. Such actions shall be at the sole expense of
                                            the Licensee and shall require approval by the IC.

 

		7.2	The
                                            IC will not be required to prepare, file, prosecute, or maintain additional patents
                                            or patent applications outside of those listed in Appendix A. The Licensee may request
                                            filing of future, related patent applications beyond those listed in Appendix A, which shall
                                            require approval by IC and will not be unreasonably denied without cause. However,
                                            in this event, the Licensee shall render direct payment for all related expenses resulting
                                            from Licensee’s requests in the manner described above in Paragraph 6.2.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 6 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

		7.3	Each
                                            party shall promptly inform the other as to all matters that come to its attention that may
                                            affect the preparation, filing, prosecution, or maintenance of the Licensed Patent Rights
                                            and any related patent applications or patents. The IC shall consult with the
                                            Licensee on the prosecution and maintenance of the Licensed Patent Rights,
                                            and permit Licensee to provide comments and suggestions with respect to the preparation,
                                            filing, prosecution, and maintenance of Licensed Patent Rights and related patent
                                            applications or patents, which shall be considered by the IC. The IC shall
                                            furnish copies of relevant patent-related documents to the Licensee upon request.

 

	8.	MATERIALS

 

		8.1	If
                                            IC Materials are provided under this Agreement, they shall be specified in
                                            Appendix A. Following receipt and verification of payment of the license issue royalty, as
                                            required by Paragraph 6.1 of this Agreement, IC shall provide the Licensee
                                            with samples of the Materials, as available, and to replace the Materials,
                                            as available, in the event of their unintentional destruction. For the avoidance of doubt,
                                            IC shall provide Materials to the Licensee solely at the Licensee’s
                                            expense as specified in Appendix G.

 

		8.2	The
                                            Licensee agrees to retain control over any Materials if provided, and the Licensed
                                            Products, and not to distribute them to third parties including Affiliate(s),
                                            but except Third Party Contractor(s) as provided in Paragraph 3.2 without the prior
                                            written consent of the IC.

 

	9.	REPORTS
                                            ON PROGRESS, BENCHMARKS, COMMERCIAL EVALUATION PLAN

 

		9.1	The
                                            Licensee shall provide written annual reports outlining results of its evaluation
                                            of the Licensed Patent Rights, the Licensed Products, Materials, and/or
                                            the Licensed Processes provided by this Agreement at the following times:

 

		(a)	by
                                            no later than thirty (30) days prior to the end of the first anniversary of the Effective
                                            Date of this Agreement; and

 

		(b)	within
                                            thirty (30) days following the second anniversary of the Effective Date of this Agreement,
                                            or termination of this Agreement, whichever occurs earlier.

 

		9.2	These
                                            reports shall describe Licensee’s efforts and progress in adhering to the Commercial
                                            Evaluation Plan for each of the Licensed Field(s) of Use. These reports shall
                                            also identify all Third-Party Contractor(s) who have received Materials or
                                            Licensed Products under this Agreement. The Licensee shall submit the
                                            report to the IC at the Mailing Address for Agreement notices indicated on
                                            the Signature Page.

 

		9.3	The
                                            Licensee’s annual written reports shall include, but not be limited to, a description
                                            of the Benchmarks achieved and described in Appendix D that occurred during the preceding
                                            calendar year:

 

		9.4	The
                                            Licensee agrees to provide sufficiently detailed information in these reports to allow
                                            the IC to reasonably evaluate Licensee’s performance and its reasonable
                                            commercial efforts, as defined in Paragraph 9.2, required under this Agreement. If
                                            requested, the Licensee agrees to provide any additional information reasonably required
                                            by the IC to evaluate the Licensee’s performance and its reasonable commercial
                                            efforts. The IC encourages these reports to include information on any of the Licensee’s
                                            public service activities that relate to the Licensed Patent Rights.

 

		9.5	All
                                            plans and reports required by this Article 10 and marked “confidential” by the
                                            Licensee shall, to the extent permitted by law, be treated by the NIH as commercial
                                            and financial information obtained from a person and as privileged and confidential, and
                                            any proposed disclosure of these records by the IC under the Freedom of Information
                                            Act (FOIA), 5 U.S.C. §552 shall be subject to the predisclosure notification
                                            requirements of 45 C.F.R. §5.65(d).

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 7 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

	10.	LICENSEE
                                            PEFFORMANCE

 

		10.1	A
                                            Commercial Evaluation Plan for this Agreement is provided in Appendix E. Based
                                            on this Commercial Evaluation Plan, performance Benchmarks are determined as
                                            specified in Appendix D.

 

		10.2	The
                                            Licensee agrees to use reasonable commercial efforts to develop the Licensed Products
                                            and the Licensed Processes. The phrase “reasonable commercial efforts”
                                            for the purposes of this and subsequent Paragraphs shall include adherence to the Commercial
                                            Evaluation Plan in Appendix E and performance of the Benchmarks by the requisite
                                            deadlines in Appendix D.

 

		10.3	If
                                            the Licensee is in default in the performance of any material obligation under this
                                            Agreement, including but not limited to, adherence to the Commercial Evaluation
                                            Plan in Appendix E and/or performance of the Benchmarks by the requisite deadlines
                                            in Appendix D, Licensee shall provide the IC with written notice within thirty
                                            (30) days of the default. Upon written approval that shall not be unreasonably withheld by
                                            the IC, the Licensee may be permitted to remedy the default within sixty (60)
                                            days after the date of written notice. The IC may terminate this Agreement
                                            by written notice if the Licensee has not reasonably remedied the default within ninety
                                            (90) days after the date of Licensee’s default.

 

		10.4	The
                                            Licensee is encouraged to publish the results of its research projects using the Licensed
                                            Patent Rights, Licensed Processes, Licensed Products or the Materials.
                                            In all oral presentations or written publications concerning the Licensed Patent Rights,
                                            Licensed Processes, Licensed Products or the Materials, the Licensee
                                            shall acknowledge the contribution by the named inventors of the Licensed Patent Rights,
                                            Licensed Processes, Licensed Products or the Materials, unless requested
                                            otherwise by the IC or the named inventors.

 

	11.	INFRINGEMENT
                                            AND PATENT ENFORCEMENT

 

		11.1	The
                                            IC and the Licensee agree to notify each other promptly of each infringement
                                            or possible infringement of the Licensed Patent Rights, as well as, any facts which
                                            may affect the validity, scope, or enforceability of the Licensed Patent Rights of
                                            which either party becomes aware.

 

		11.2	Pursuant
                                            to this Agreement and the provisions of 35 U.S.C. Chapter 29, the Licensee
                                            may:

 

		(a)	bring
                                            suit in its own name, at its own expense, and on its own behalf for infringement of presumably
                                            valid claims in the Licensed Patent Rights;

 

		(b)	in
                                            any suit, enjoin infringement and collect for its use, damages, profits, and awards of whatever
                                            nature recoverable for the infringement; or

 

		(c)	settle
                                            any claim or suit for infringement of the Licensed Patent Rights provided, however,
                                            that the IC and appropriate Government authorities shall have the first right
                                            to take such actions; and

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 8 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

		(d)	if
                                            the Licensee desires to initiate a suit for patent infringement, the Licensee
                                            shall notify the IC in writing. If the IC does not notify the Licensee
                                            of its intent to pursue legal action within ninety (90) days, the Licensee shall be
                                            free to initiate suit. The IC shall have a continuing right to intervene in the suit.
                                            The Licensee shall take no action to compel the Government either to initiate
                                            or to join in any suit for patent infringement. The Licensee may request the Government
                                            to initiate or join in any suit if necessary to avoid dismissal of the suit. Should the
                                            Government be made a party to any suit, the Licensee shall reimburse the Government
                                            for any costs, expenses, or fees which the Government incurs as a result of the
                                            motion or other action, including all costs incurred by the Government in opposing
                                            the motion or other action. In all cases, the Licensee agrees to keep the IC
                                            reasonably apprised of the status and progress of any litigation. Before the Licensee
                                            commences an infringement action, the Licensee shall notify the IC and
                                            give careful consideration to the views of the IC and to any potential effects of
                                            the litigation on the public health in deciding whether to bring suit.

 

		11.3	In
                                            the event that a declaratory judgment action alleging invalidity or non-infringement of any
                                            of the Licensed Patent Rights shall be brought against the Licensee or raised
                                            by way of counterclaim or affirmative defense in an infringement suit brought by the Licensee
                                            under Paragraph 11.2, pursuant to this Agreement and the provisions of 35 U.S.C.
                                            Chapter 29 or other statutes, the Licensee may:

 

		(a)	defend
                                            the suit in its own name, at its own expense, and on its own behalf for presumably valid
                                            claims in the Licensed Patent Rights;

 

		(b)	in
                                            any suit, ultimately to enjoin infringement and to collect for its use, damages, profits,
                                            and awards of whatever nature recoverable for the infringement; and

 

		(c)	settle
                                            any claim or suit for declaratory judgment involving the Licensed Patent Rights-provided,
                                            however, that the IC and appropriate Government authorities shall have the
                                            first right to take these actions and shall have a continuing right to intervene in the suit;
                                            and

 

		(d)	if
                                            the IC does not notify the Licensee of its intent to respond to the legal action
                                            within a reasonable time, the Licensee shall be free to do so. The Licensee
                                            shall take no action to compel the Government either to initiate or to join in any
                                            declaratory judgment action. The Licensee may request the Government to initiate
                                            or to join any suit if necessary to avoid dismissal of the suit. Should the Government
                                            be made a party to any suit by motion or any other action of the Licensee, the
                                            Licensee shall reimburse the Government for any costs, expenses, or fees, which
                                            the Government incurs as a result of the motion or other action. If the Licensee
                                            elects not to defend against the declaratory judgment action, the IC, at its option,
                                            may do so at its own expense. In all cases, the Licensee agrees to keep the IC
                                            reasonably apprised of the status and progress of any litigation. Before the Licensee
                                            commences an infringement action, the Licensee shall notify the IC and
                                            give careful consideration to the views of the IC and to any potential effects of
                                            the litigation on the public health in deciding whether to bring suit.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 9 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

		11.4	In
                                            any action under Paragraphs 11.2 or 11.3 the expenses including costs, fees, attorney fees,
                                            and disbursements, shall be paid by the Licensee. The value of any recovery made by
                                            the Licensee through court judgment or settlement shall be treated as Net Sales
                                            and subject to earned royalties.

 

		11.5	The
                                            IC shall cooperate fully with the Licensee in connection with any action under
                                            Paragraphs 11.2 or 11.3. The IC agrees promptly to provide access to all necessary
                                            documents and to render reasonable assistance in response to a request by the Licensee.

 

	12.	NEGATION
                                            OF WARRANTIES AND INDEMNIFICATION

 

		12.1	The
                                            IC offers no warranties other than those specified in Article 1.

 

		12.2	The
                                            IC does not warrant the validity of the Licensed Patent Rights and makes no
                                            representations whatsoever with regard to the scope of the Licensed Patent Rights,
                                            or that the Licensed Patent Rights may be exploited without infringing other patents
                                            or other intellectual property rights of third parties.

 

		12.3	THE
                                            IC MAKES NO WARRANTIES, EXPRESS OR IMPLIED, OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR
                                            PURPOSE OF ANY SUBJECT MATTER DEFINED BY THE CLAIMS OF THE LICENSED PATENT RIGHTS
                                            OR TANGIBLE MATERIALS RELATED THERETO.

 

		12.4	The
                                            IC does not represent that it shall commence legal actions against third parties infringing
                                            the Licensed Patent Rights.

 

		12.5	The
                                            Licensee shall indemnify and hold the IC, its employees, students, fellows,
                                            agents, and consultants harmless from and against all liability, demands, damages, expenses,
                                            and losses, including but not limited to death, personal injury, illness, or property damage
                                            in connection with or arising out of:

 

		(a)	the
                                            use by or on behalf of the Licensee, its sublicensees, directors, employees, or third
                                            parties of any Licensed Patent Rights; or

 

		(b)	the
                                            design, manufacture, distribution, or use of any Licensed Products, Licensed Processes
                                            or materials by the Licensee, or other products or processes developed in connection
                                            with or arising out of the Licensed Patent Rights.

 

		12.6	The
                                            Licensee agrees to maintain a liability insurance program consistent with sound business
                                            practice.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 10 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

	13.	TERM,
                                            TERMINATION, AND MODIFICATION OF RIGHTS

 

		13.1	This
                                            Agreement shall become effective as of the Effective Date unless the provisions
                                            of Paragraph 14.16 are not fulfilled and shall expire twenty-four (24) months from its Effective
                                            Date. Within sixty (60) days of the termination or expiration of this Agreement,
                                            unless an IC Exclusive or Non-exclusive Commercial Patent License has been executed
                                            for the Licensed Patent Rights in the Licensed Field(s) of Use, as stipulated
                                            in Paragraph 3.3 of this Agreement, the Licensee shall return all Materials
                                            and Licensed Products to the IC or provide the IC with written certification
                                            of their destruction. The Licensee further agrees that it shall be responsible for
                                            the destruction of any remaining Materials and Licensed Products from the Third
                                            Party Contractor(s) to the Licensee, and the Licensee shall obtain written
                                            certification from the Third Party Contractor(s) that any remaining Materials
                                            or Licensed Products in their possession have been destroyed and to provide IC
                                            with a copy of said written notification within sixty (60) days of the termination or
                                            expiration of this Agreement.

 

		13.2	The
                                            IC reserves the right according to 35 U.S.C. §209(d)(3) to terminate or
                                            modify this Agreement if it determines that this action is necessary to meet the requirements
                                            for public use specified by federal regulations issued after the date of the license and
                                            these requirements are not reasonably satisfied by the Licensee.

 

		13.3	The
                                            IC shall specifically have the right to terminate or modify this Agreement,
                                            at its sole option, if the IC determines that the Licensee:

 

		(a)	has
                                            not adhered to the Commercial Evaluation Plan in Appendix E, as may be amended by
                                            mutual agreement of the parties;

 

		(b)	has
                                            not performed or has not exercised reasonable commercial efforts towards performance of the
                                            Benchmarks by the requisite deadlines specified in Appendix D, as may be modified
                                            under Paragraph 10.3;

 

		(c)	has
                                            willfully made a false statement or willfully omitted a material fact in the license application
                                            or in any report required by this Agreement;

 

		(d)	has
                                            committed a material breach of a covenant or agreement contained in this Agreement;
                                            or

 

		(e)	cannot
                                            reasonably satisfy unmet health and safety needs.

 

		13.4	Within
                                            thirty (30) days of receipt of written notice of the IC’s unilateral decision
                                            to modify or terminate this Agreement, the Licensee may, consistent with the
                                            provisions of 37 C.F.R. §404.11, appeal the decision by written submission to
                                            the designated IC official or designee. The decision of the designated IC official
                                            or designee shall be the final agency decision. The Licensee may thereafter exercise
                                            all administrative or judicial remedies that may be accessible.

 

		13.5	The
                                            Licensee shall have a unilateral right to terminate this Agreement or any licenses
                                            in any country or territory by giving the IC sixty (60) days written notice to that
                                            effect.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 11 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

 

		13.6	Within
                                            thirty (30) days of expiration or termination of this Agreement under this Article
                                            13, a final written report shall be submitted by the Licensee in accordance with Paragraph
                                            9.1. The Licensee may not be granted additional IC licenses if this final reporting
                                            requirement is not fulfilled. Any royalty payments, including those incurred but not yet
                                            paid, and those related to patent expenses, due to the IC shall become immediately
                                            due and payable upon termination or expiration.

 

		14.	GENERAL
                                            PROVISIONS

 

		14.1	Neither
                                            party may waive or release any of its rights or interests in this Agreement except
                                            in writing. The failure of the Government to assert a right hereunder or to insist
                                            upon compliance with any term or condition of this Agreement shall not constitute
                                            a waiver of that right by the Government or excuse a similar subsequent failure to
                                            perform any of these terms or conditions by the Licensee.

 

		14.2	This
                                            Agreement constitutes the entire agreement between the parties relating to the subject
                                            matter of the Licensed Patent Rights, the Licensed Products and the Licensed
                                            Processes, and all prior negotiations, representations, agreements, and understandings
                                            are merged into, extinguished by, and completely expressed by this Agreement.

 

		14.3	The
                                            provisions of this Agreement are severable, and in the event that any provision of
                                            this Agreement shall be determined to be invalid or unenforceable under any controlling
                                            body of law, this determination shall not in any way affect the validity or enforceability
                                            of the remaining provisions of this Agreement.

 

		14.4	If
                                            either party desires a modification to this Agreement, the parties shall, upon reasonable
                                            notice of the proposed modification by the party desiring the change, confer in good faith
                                            to determine the desirability of the modification. No modification shall be effective until
                                            a written amendment is signed by the signatories to this Agreement or their designees.

 

		14.5	The
                                            construction, validity, performance, and effect of this Agreement shall be governed
                                            by Federal law as applied by the Federal courts in the District of Columbia.

 

		14.6	All
                                            Agreement notices required or permitted by this Agreement shall be given by
                                            prepaid, first class, registered or certified mail or by an express/overnight delivery service
                                            provided by a commercial carrier, properly addressed to the other party at the address designated
                                            on the following Signature Page, or to another address as may be designated in writing by
                                            the other party. Agreement notices shall be considered timely if the notices are received
                                            on or before the established deadline date or sent on or before the deadline date as verifiable
                                            by U.S. Postal Service postmark or dated receipt from a commercial carrier. Parties should
                                            request a legibly dated U.S. Postal Service postmark or obtain a dated receipt from a commercial
                                            carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as
                                            proof of timely mailing.

 

		14.7	This
                                            Agreement shall not be assigned or otherwise transferred (including any transfer by
                                            legal process or by operation of law, and any transfer in bankruptcy or insolvency, or in
                                            any other compulsory procedure or order of court) except to the Licensee’s Affiliate(s)
                                            without the prior written consent of the IC. The parties agree that the identity
                                            of the parties is material to the formation of this Agreement and that the obligations
                                            under this Agreement are nondelegable. In the event that the IC approves a
                                            proposed assignment, the Licensee shall pay the IC, as an additional royalty,
                                            one percent (1%) of the fair market value of any consideration received for any assignment
                                            of this Agreement within sixty (60) days of the assignment.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 12 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

		14.8	The
                                            Licensee agrees in its use of any IC-supplied materials to comply with all
                                            applicable statutes, regulations, and guidelines, including NIH and HHS regulations
                                            and guidelines. The Licensee agrees not to use the Materials for research involving
                                            human subjects or clinical trials.

 

		14.9	By
                                            entering into this Agreement, the IC does not directly or indirectly endorse
                                            any product or service provided, or to be provided, by the Licensee whether directly
                                            or indirectly related to this Agreement. The Licensee shall not state or imply
                                            that this Agreement is an endorsement by the Government, the IC, any
                                            other Government organizational unit, or any Government employee. Additionally,
                                            the Licensee shall not use the names of the IC, the FDA or the HHS
                                            or the Government or their employees in any advertising, promotional, or sales
                                            literature without the prior written approval of the IC.

 

		14.10	The
                                            parties agree to attempt to settle amicably any controversy or claim arising under this Agreement
                                            or a breach of this Agreement, except for appeals of modifications or termination
                                            decisions provided for in Article 13. The Licensee agrees first to appeal any unsettled
                                            claims or controversies to the designated IC official, or designee, whose decision
                                            shall be considered the final agency decision. Thereafter, the Licensee may exercise
                                            any administrative or judicial remedies that may be available.

 

		14.11	Nothing
                                            relating to the grant of a license, nor the grant itself, shall be construed to confer upon
                                            any person any immunity from or defenses under the antitrust laws or from a charge of patent
                                            misuse, and the acquisition and use of rights pursuant to 37 C.F.R. Part 404 shall
                                            not be immunized from the operation of state or Federal law by reason of the source of the
                                            grant.

 

		14.12	Any
                                            formal recordation of this Agreement required by the laws of any Licensed Territory
                                            as a prerequisite to enforceability of the Agreement in the courts of any foreign
                                            jurisdiction or for other reasons shall be carried out by the Licensee at its expense,
                                            and appropriately verified proof of recordation shall be promptly furnished to the IC.

 

		14.13	Paragraphs
                                            9, 10.4, 12, 13.4, 13.6, 14.10 and 14.13 of this Agreement shall survive termination
                                            of this Agreement.

 

		14.14	The
                                            terms and conditions of this Agreement shall, at the IC’s sole option,
                                            be considered by the IC to be withdrawn from the Licensee’s consideration
                                            and the terms and conditions of this Agreement, and the Agreement itself to
                                            be null and void, unless this Agreement is executed by the Licensee and a fully
                                            executed original is received by the IC within sixty (60) days from the date of the
                                            IC’s signature found at the Signature Page.

 

SIGNATURES
BEGIN ON NEXT PAGE

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 13 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

NIH
PATENT LICENSE AGREEMENT – EXCLUSIVE

 

SIGNATURE
PAGE

 

For
the IC:

 

	 /s/
Richard Rodriguez 	 	_______________
	Richard
    U. Rodriguez	 	Date

Associate
Director

Technology
Transfer Center

National
Cancer Institute

National
Institute of Health

 

Mailing
Address or E-mail Address for Agreement notices and reports:

 

Chief,
Monitoring & Enforcement Branch

Office
of Technology Transfer

National
Institutes of Health

6011
Executive Boulevard, Suite 325

Rockville,
Maryland 20852-3804 U.S.A.

 

E-mail:
LicenseNotices_Reports@mail.nih.gov

 

For
the Licensee (upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements
of the Licensee made or referred to in this document are truthful and accurate):

 

	by:	 	 
	 	 	 
	 /s/
    Paul Michaels 	 	 
	Signature
    of Authorized Official	 	Date
	 	 	 
	Paul
    Michaels	 	 
	Printed
    Name	 	 
	 	 	 
	Chief
    Executive Officer	 	 
	Title	 	 

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 14 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

	 	I.	Official
    and Mailing Address for Agreement notices:	 
	 	 	 	 	 
	 	 	Paul
    Michaels	 
	 	 	Name	 	 
	 	 	Chief
    Executive Officer	 
	 	 	Title	 	 
	 	 	 	 	 
	 	 	Mailing
    Address	 	 
	 	 	 	 	 
	 	 	Connectyx
    Technologies Holdings Group	 
	 	 	1825
    NW Corporate Boulevard, Suite 110	 
	 	 	Boca
    Raton, FL 33431	 
	 	 	 	 
	 	 	 	 	 
	 	 	Email
    Address:	pmichaels@connectyx.com	 
	 	 	 	 	 
	 	 	Phone:	561-418-7725	 
	 	 	 	 	 
	 	 	Fax:	561-418-7724	 

 

	 	II.	Official and Mailing Address for Financial notices (the Licensee’s contact person for royalty payments)
	 	 	 	 	 
	 	 	Paul
    Michaels	 
	 	 	Name	 	 
	 	 	 	 	 
	 	 	Chief
    Executive Officer	 
	 	 	Title	 	 
	 	 	 	 	 
	 	 	Mailing
    Address:	 	 
	 	 	 	 	 
	 	 	Connectyx
    Technologies Holdings Group	 
	 	 	1825
    NW Corporate Boulevard, Suite 110	 
	 	 	Boca
    Raton, FL 33431	 
	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	Email
    Address:	pmichaels@connectyx.com	 
	 	 	 	 	 
	 	 	Phone:	561-418-7725	 
	 	 	 	 	 
	 	 	Fax:	561-418-7724	 

 

Any
false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement
and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including
Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including
fine(s) or imprisonment).

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 15 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

APPENDIX
A – Patent(s) or Patent Application(s)

 

HHS
Ref. No. E-221-2015-0

 

Entitled:
“ANTIBODY - DRUG CONJUGATES FOR TARGETING CD56 - POSITIVE TUMORS”

 

Inventors:
Dimiter S. Dimitrov, Yang Feng, and Zhongyu Zhu (NCI), and John M. Maris, Robyn Tovah Sussman (Children’s Hospital of Philadelphia
“CHOP”).

 

	IV.	U.S.
                                            Provisional Patent Application No. 62/119,707 filed July 31, 2015. HHS Ref No. E-221-2015-0-US-01

 

	V.	PCT
                                            Application No. PCT/US2016/044777 filed 07/29/2016. HHS Ref. No. E-221-2015-0-PCT-02

 

	VI.	US
                                            Patent No. 10,548,987 issued February 04, 2020 (Patent Application No. 15/747,620 filed January
                                            25, 2018). HHS Ref. No. E-221-2015-0-US-03.

 

		Materials:	

 

		1.	purified
                                            CD56 antibody: 5mg of m906 and 0.6 mg m900

 

		2.	m906
                                            production CHO cell line: 1 vial

 

		3.	plasmids
                                            for m900 and m906: 10 ug of each

 

		4.	m906-PBD:
                                            0.5mg

 

Additional
materials may be provided under a separate license agreement.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 16 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

APPENDIX
B – Licensed Fields of Use and Territory

 

	I.	Licensed
                                            Field(s) of Use: The use of the anti-CD56 to develop an antibody-drug conjugate (“ADC”)
                                            to target glioblastoma either alone or in combination with other potential immuno-oncology
                                            drugs.

 

	II.	Licensed
                                            Territory: Worldwide

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 17 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

APPENDIX
C – Royalties

 

Royalties:

 

	I.	The
                                            Licensee agrees to pay to the IC a non-creditable, non-refundable license issue
                                            royalty according to the following schedule:

 

		(a)	Five
                                            thousand US dollars ($5,000.00 USD) within sixty (60) days of the Effective Date of
                                            this Agreement. 

 

	II.	The
                                            Licensee agrees to pay to the IC a non-creditable, non-refundable patent reimbursement
                                            royalty according to the following schedule:

 

		(a)	Five
                                            thousand US dollars ($5,000.00 USD) on the one-year anniversary of the Effective Date
                                            of this Agreement. 

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 18 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

APPENDIX
D – Benchmarks and Performance

 

The
Licensee agrees to the following Benchmarks for its performance under this Agreement and, within thirty (30) days
of achieving a Benchmark, shall notify the IC that the Benchmark has been achieved.

 

	I.	Initiate
                                            preclinical IND-enabling studies within six (6) months of the Effective Date of the
                                            Agreement.

 

	II.	Select
                                            at least one lead ADC candidate within eighteen (18) months of the Effective Date of
                                            the Agreement.

 

	III.	Raise
                                            at least at total of $500,000.00 within twenty-two (22) months of the Effective Date of
                                            the Agreement.

 

	IV.	IND
                                            Submission within twenty-four (24) months of the Effective Date of the Agreement.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 19 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

APPENDIX
E – Commercial EVALUATION Plan

 

The
company will initially be virtual, relying heavily on contract vendors to conduct nonclinical studies required for IND submission. Both
m900 and m906 linked to PBD will be evaluated to further characterize the ADCs and to determine their stability, solubility, etc. as
shown in the two figures below. Depending on the nonclinical data and outcomes, the company will use the nonclinical data to tailor their
clinical trials to enable rapid transition from safety to pivotal using the fewest subjects possible. The plan is to select one of the
two antibodies for further development and select one or two leads for IND consideration by the expiration of this Agreement. Additional
evaluation and development plan detailed the application.

 

 

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 20 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

Appendix
F – Royalty Payment Options

 

New
Payment Options Effective March 2018

 

The
License Number MUST appear on payments, reports and correspondence.

 

Credit
and Debit Card Payments: Credit and debit card payments can be submitted for amounts up to $24,999. Submit your payment through the
U.S. Treasury web site located at: https://www.pay.gov/public/form/start/28680443.

 

Automated
Clearing House (ACH) for payments through U.S. banks only

 

The
IC encourages its licensees to submit electronic funds transfer payments through the Automated Clearing House (ACH). Submit your
ACH payment through the U.S. Treasury web site located at: https://www.pay.gov/public/form/start/28680443. Please note that the
IC “only” accepts ACH payments through this U.S. Treasury web site.

 

Electronic
Funds Wire Transfers: The following account information is provided for wire payments. In order to process payment via Electronic
Funds Wire Transfer sender MUST supply the following information within the transmission:

 

Drawn
on a U.S. bank account via FEDWIRE:

 

Please
provide the following instructions to your Financial Institution for the remittance of Fedwire payments to the NIH ROYALTY FUND.

 

	Fedwire
    Field Tag	 	Fedwire
    Field Name	 	Required
    Information
	 	 	 	 	 
	{1510}	 	Type/Subtype	 	1000
	{2000}	 	Amount	 	(enter
    payment amount)
	{3400}	 	Receiver
    ABA routing number*	 	021030004
	{3400}	 	Receiver
    ABA short name	 	TREAS
    NYC
	{3600}	 	Business
    Function Code	 	CTR
    (or CTP)
	{4200}	 	Beneficiary
    Identifier (account number)	 	(enter
                                            12 digit gateway account #)

    875080031006

	{4200}	 	Beneficiary
    Name	 	(enter
                                            agency name associated with the Beneficiary Identifier)

    DHHS
    / NIH (75080031)

	{5000}	 	Originator	 	(enter
                                            the name of the originator of the payment)

    COMPANY
    NAME

	{6000}	 	Originator
    to Beneficiary Information – Line 1	 	(enter
                                            information to identify the purpose of the payment)

    ROYALTY

	{6000}	 	Originator
    to Beneficiary Information – Line 2	 	(enter
                                            information to identify the purpose of the payment)

     

    LICENSE
    NUMBER

	{6000}	 	Originator
    to Beneficiary Information – Line 3	 	(enter
                                            information to identify the purpose of the payment)

    INVOICE
    NUMBER

	{6000}	 	Originator
    to Beneficiary Information – Line 4	 	(enter
    information to identify the purpose of the payment)

 

Notes:

*The
financial institution address for Treasury’s routing number is 33 Liberty Street, New York, NY 10045.

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 21 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

Agency
Contacts: Office of Technology Transfer (OTT) (301) 496-7057 OTT-Royalties@mail.nih.gov

 

Drawn
on a foreign bank account via FEDWIRE:

 

The
following instructions pertain to the Fedwire Network. Deposits made in US Dollars (USD).

 

Should
your remitter utilize a correspondent US domestic bank in transferring electronic funds, the following Fedwire instructions are applicable.

 

	Fedwire
    Field Tag	 	Fedwire
    Field Name	 	Required
    Information
	 	 	 	 	 
	{1510}	 	Type/Subtype	 	1000
	{2000}	 	Amount	 	(enter
    payment amount)
	{3100}	 	Sender
    Bank ABA routing number	 	(enter
    the US correspondent bank’s ABA routing number)
	{3400}	 	Receiver
    ABA routing number*	 	021030004
	{3400}	 	Receiver
    ABA short name	 	TREAS
    NYC
	{3600}	 	Business
    Function Code	 	CTR
    (or CTP)
	{4200}	 	Beneficiary
    Identifier (account number)**	 	(enter
                                            12 digit gateway account #)

    

    875080031006

	{4200}	 	Beneficiary
    Name	 	(enter
                                            agency name associated with the Beneficiary Identifier)

    

    DHHS
    / NIH (75080031)

	{5000}	 	Originator	 	(enter
                                            the name of the originator of the payment)

    

    COMPANY’S
    NAME

	{6000}	 	Originator
    to Beneficiary Information – Line 1	 	(enter
                                            information to identify the purpose of the payment)

    

    ROYALTY

	{6000}	 	Originator
    to Beneficiary Information – Line 2	 	(enter
                                            information to identify the purpose of the payment)

    

    LICENSE
    NUMBER

	{6000}	 	Originator
    to Beneficiary Information – Line 3	 	(enter
                                            information to identify the purpose of the payment)

    

    INVOICE
    NUMBER

	{6000}	 	Originator
    to Beneficiary Information – Line 4	 	(enter
    information to identify the purpose of the payment)

 

Notes:

*The
financial institution address for Treasury’s routing number is 33 Liberty Street, New York, NY 10045.

**Anything
other than the 12 digit gateway account # will cause the Fedwire to be returned – SWIFT CODE: FRNYUS33

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 22 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

Agency
Contacts:

 

Office
of Technology Transfer (OTT) (301) 496-7057 OTT-Royalties@mail.nih.gov

 

Checks

 

All
checks should be made payable to “NIH Patent Licensing”

 

Checks
drawn on a U.S. bank account and sent by US Postal Service should be sent directly to the following address:

 

National
Institutes of Health

P.O.
Box 979071

St.
Louis, MO 63197-9000

 

Checks
drawn on a U.S. bank account and sent by overnight or courier should be sent to the following address:

 

US
Bank

Government
Lockbox SL-MO-C2GL

1005
Convention Plaza

St.
Louis, MO 63101

Phone:
314-418-4087

 

Checks
drawn on a foreign bank account should be sent directly to the following address:

 

National
Institutes of Health

Office
of Technology Transfer

License
Compliance and Administration

Royalty
Administration

6011
Executive Boulevard

Suite
325, MSC 7660

Rockville,
Maryland 20852

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 23 of 24 [Draft2] [Connectyx] [2020 September]

 

    	 

    	 

    

 

APPENDIX
G – SHIPPING INFORMATION

 

The
Licensee’s Shipping Contact: information or questions regarding shipping should be directed to the Licensee’s Shipping
Contact at:

 

	 	 	 	 
	Shipping
    Contact’s Name	 	 	Title	 
	 	 	 	 	 	 
	Phone:	()	Fax:	()	E-mail:	 

 

Shipping
Address: Name & Address to which Materials should be shipped (please be specific):

 

 ____________________________________

Company
Name & Department

 

Address:

 _________________________________

 

 _________________________________

 

 _________________________________

 

 _________________________________

 

The
Licensee’s shipping carrier and account number to be used for shipping purposes:

 

__________________________________________________________________

 

CONFIDENTIAL

NIH
Patent License Agreement--Exclusive

Model
10-2015 Page 24 of 24 [Draft2] [Connectyx] [2020 September]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]